ZYNERBA PHARMACEUTICALS INC (ZYNE) Stock Price, Quote, News and Overview
NASDAQ:ZYNE - Nasdaq - US98986X1090 - Common Stock - Currency: USD
ZYNE Quote, Performance and Key Statistics
1.3
+0.03 (+2.36%)
The current stock price of ZYNE is 1.3 USD. In the past month the price decreased by -1.52%. In the past year, price increased by 89.61%.
ZYNE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ZYNE
Company Profile
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2015-08-05. The firm is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). The company is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). The company uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).
Company Info
ZYNERBA PHARMACEUTICALS INC
80 W. Lancaster Avenue, Suite 300
Devon PENNSYLVANIA 19333 US
CEO: Armando Anido
Employees: 25
Company Website: https://www.zynerba.com/
Phone: 14845817505.0
ZYNERBA PHARMACEUTICALS INC / ZYNE FAQ
What is the stock price of ZYNERBA PHARMACEUTICALS INC today?
The current stock price of ZYNE is 1.3 USD. The price increased by 2.36% in the last trading session.
What is the ticker symbol for ZYNERBA PHARMACEUTICALS INC stock?
The exchange symbol of ZYNERBA PHARMACEUTICALS INC is ZYNE and it is listed on the Nasdaq exchange.
On which exchange is ZYNE stock listed?
ZYNE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZYNERBA PHARMACEUTICALS INC stock?
9 analysts have analysed ZYNE and the average price target is 1.28 USD. This implies a price decrease of -1.53% is expected in the next year compared to the current price of 1.3. Check the ZYNERBA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZYNERBA PHARMACEUTICALS INC worth?
ZYNERBA PHARMACEUTICALS INC (ZYNE) has a market capitalization of 70.12M USD. This makes ZYNE a Micro Cap stock.
How many employees does ZYNERBA PHARMACEUTICALS INC have?
ZYNERBA PHARMACEUTICALS INC (ZYNE) currently has 25 employees.
What are the support and resistance levels for ZYNERBA PHARMACEUTICALS INC (ZYNE) stock?
ZYNERBA PHARMACEUTICALS INC (ZYNE) has a support level at 1.3 and a resistance level at 1.35. Check the full technical report for a detailed analysis of ZYNE support and resistance levels.
Should I buy ZYNERBA PHARMACEUTICALS INC (ZYNE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZYNE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZYNE, evaluating the profitability, health, valuation and growth aspects
- ZYNERBA PHARMACEUTICALS INC (ZYNE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZYNERBA PHARMACEUTICALS INC (ZYNE) Sales and EPS estimates to see what analysts future expectations are.
- ZYNERBA PHARMACEUTICALS INC (ZYNE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZYNERBA PHARMACEUTICALS INC (ZYNE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZYNERBA PHARMACEUTICALS INC (ZYNE) Stock Chart to make your own analysis
- ZYNERBA PHARMACEUTICALS INC (ZYNE) Latest news and press-releases to stay up to date.
Does ZYNERBA PHARMACEUTICALS INC (ZYNE) stock pay dividends?
ZYNE does not pay a dividend.
When does ZYNERBA PHARMACEUTICALS INC (ZYNE) report earnings?
ZYNERBA PHARMACEUTICALS INC (ZYNE) will report earnings on 2023-11-13, before the market open.
What is the Price/Earnings (PE) ratio of ZYNERBA PHARMACEUTICALS INC (ZYNE)?
ZYNERBA PHARMACEUTICALS INC (ZYNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).
ZYNE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ZYNE. When comparing the yearly performance of all stocks, ZYNE is one of the better performing stocks in the market, outperforming 99.66% of all stocks.
ZYNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZYNE. ZYNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ZYNE Financial Highlights
Over the last trailing twelve months ZYNE reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 13.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.85% | ||
| ROE | -129.5% | ||
| Debt/Equity | 0 |
ZYNE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to ZYNE. The Buy consensus is the average rating of analysts ratings from 9 analysts.